Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.35 |
| ▸ | MAT2A | P31153 | 2/20 | 0.35 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | VHL | P40337 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11298609 | 0.69 | MKNK1 (0.48) | SMN1; SMN2POLBEP300KAT2BALDH1A1 | |
| SCHEMBL14446911 | 0.64 | SMN1; SMN2 (0.50) | SMN1; SMN2POLBCYP1A2SLC11A2EP300 | |
| SCHEMBL12661008 | 0.63 | EP300 (0.53) | SMN1; SMN2POLBSLC11A2EP300KAT2B | |
| SCHEMBL28379997 | 0.62 | SMN1; SMN2 (0.55) | SMN1; SMN2POLBSLC11A2EP300KAT2B | |
| SCHEMBL30356365 | 0.61 | KMT2A (0.44) | SMN1; SMN2POLBSLC11A2MAT2AALDH1A1 | |
| SCHEMBL10027622 | 0.61 | POLB (0.43) | SMN1; SMN2POLBMAT2AEP300KAT2B | |
| SCHEMBL4675341 | 0.61 | SMN1; SMN2 (0.53) | SMN1; SMN2POLBEP300KAT2BPDCD1 | |
| SCHEMBL30436933 | 0.61 | SMN1; SMN2 (0.53) | SMN1; SMN2POLBEP300KAT2BPDCD1 | |
| SCHEMBL14446902 | 0.61 | SMN1; SMN2 (0.50) | SMN1; SMN2POLBCYP1A2SLC11A2EP300 | |
| SCHEMBL30174279 | 0.61 | MAPK14 (0.52) | SMN1; SMN2POLBSLC11A2PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | TNF, TNFRSF1A, TNFRSF9 | SMN1; SMN2 2010/4885POLB 1737/4885CYP1A2 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.